Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4789939
Max Phase: Preclinical
Molecular Formula: C35H58N8O6S2
Molecular Weight: 751.03
Molecule Type: Unknown
Associated Items:
ID: ALA4789939
Max Phase: Preclinical
Molecular Formula: C35H58N8O6S2
Molecular Weight: 751.03
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CNC(=O)COCC(=O)NCCCCNC(=O)COCC(=O)NC[C@H]1CC[C@H](/N=C(\NC2CCCCC2)SCC2=CSC3=NC(C)(C)CN23)CC1
Standard InChI: InChI=1S/C35H58N8O6S2/c1-35(2)24-43-28(23-51-34(43)42-35)22-50-33(40-26-9-5-4-6-10-26)41-27-13-11-25(12-14-27)17-39-32(47)21-49-20-31(46)38-16-8-7-15-37-30(45)19-48-18-29(44)36-3/h23,25-27H,4-22,24H2,1-3H3,(H,36,44)(H,37,45)(H,38,46)(H,39,47)(H,40,41)/t25-,27-
Standard InChI Key: CFYAXNRXEOCJSZ-DUYHBEBVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 751.03 | Molecular Weight (Monoisotopic): 750.3921 | AlogP: 2.50 | #Rotatable Bonds: 19 |
Polar Surface Area: 174.85 | Molecular Species: BASE | HBA: 11 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 8.72 | CX LogP: 0.70 | CX LogD: -0.61 |
Aromatic Rings: 0 | Heavy Atoms: 51 | QED Weighted: 0.08 | Np Likeness Score: -0.71 |
1. Ma H,Wang H,Li M,Barreto-de-Souza V,Reinecke BA,Gunta R,Zheng Y,Kang G,Nassehi N,Zhang H,An J,Selley DE,Hauser KF,Zhang Y. (2020) Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry., 11 (11): [PMID:33214847] [10.1021/acsmedchemlett.0c00444] |
Source(1):